Analytical Data
-
Gene name
HLA-A*24:02&B2M&EBV EBNA3A(RYSIFFDYM) Monomer
- Application
-
Alternative Names
HLA-A*2402 & B2M & EBV EBNA3A (RYSIFFDYM)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59600.1 (G25-T305)&P61769
-
Expression Region
AAA59600.1 (G25-T305)&P61769 (I21-M119)&RYSIFFDYM
-
Molecular Weight
40-43 kDa and 12 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*24:02 is a prevalent human leukocyte antigen (HLA) class I molecule, particularly associated with certain autoimmune diseases and cancers in East Asian populations. Understanding its interaction with various peptides is crucial for advancing immunotherapy and vaccine design. Among the peptides presented by HLA-A*24:02, EBV (Epstein-Barr Virus) EBNA3A (specifically the peptide RYSIFFDYM) is of significant interest due to its role in viral persistence and its potential as a target for T cell-based therapies. The combination of HLA-A*24:02 and the peptide can provide insights into T cell receptor (TCR) recognition and specificity, which is vital for developing effective immunotherapeutic strategies against EBV-associated malignancies. Recombinant protein studies of the HLA-A*24:02, beta-2-microglobulin (B2M), and EBNA3A complex allow for the exploration of structural and functional aspects of the peptide-MHC interaction. These investigations can enhance our understanding of the immune response mechanisms and facilitate the design of targeted therapies for diseases related to EBV, thereby contributing to the broader field of immunology and personalized medicine.
